Skip to content
Matrix Global Advisors
Matrix Global Advisors
  • Home
  • About
  • News
  • Our Work
  • Contact
  • Home
  • About
  • News
  • Our Work
  • Contact
Sep222020
News

Ending Prescription Drug ‘Product Hopping’ Could Save $4.7 Billion Annually

Scott Wooldridge | BenefitsPro

“The report, from Matrix Global Advisors and the Coalition for Affordable Prescription Drugs (CAPD), looked at five prescription drugs: Prilosec, TriCor, Suboxone, Doryx, and Namenda. As with other examples of product hopping, drug companies have tweaked the formulas on those drugs, allowing them to extend their patents on the new formulations, and delay the move to the generic drug marketplace.

The report finds that extending patents on just those five drugs will result in a cost to the U.S. health care system of $4.7 billion annually—money that in theory could have been saved if the drugs had been available in a generic form.”

Read Here (Registration Required)

September 22, 2020Category: News
Tags: drug competitiongeneric drugproduct hopping

Post navigation

PreviousPrevious post:Trump Roils Markets with Conflicting Statements on Pandemic ReliefNextNext post:A Deal for Coronavirus Fiscal Relief
  • Analysis(27)
  • Books(2)
  • Events(13)
  • Interviews(33)
  • News(43)
  • Op-Eds(59)
  • Press Releases(2)
  • Testimony(18)
  • Almost-Speaker McCarthy
    November 23, 2020
  • Nursing Homes Prepare for Third COVID-19 Surge
    October 26, 2020
  • Impact of the Coronavirus Pandemic on Red, Blue, and Swing States
    October 20, 2020
  • Trump Roils Markets with Conflicting Statements on Pandemic Relief
    October 7, 2020

Website Design and Developed by DreamBig Creative